Synopsis: In a striking coincidence of timing, ace investor Mukul Mahavir Agrawal reduced his stake in OneSource Specialty Pharma to below 1% just weeks before the company announced a landmark U.S. FDA approval for a generic version of the global blockbuster drug, Ozempic. While the “whale” investor may have pared his position, the stock price surged as the market pivoted toward the massive commercial potential of Semaglutide.
The latest shareholding pattern for OneSource Specialty Pharma Limited reveals a notable shift in institutional sentiment. Mukul Mahavir Agrawal, a revered figure in the Indian small-cap space, held a 1.05% stake as of December 2025.
However, the March 2026 data shows his name missing from the list of shareholders holding less than 1%, implying he has either significantly reduced his exposure or exited entirely. Usually, a “Super Investor” exit triggers a sell-off. However, the narrative for OneSource was completely rewritten on April 21, 2026.
The company announced that its partner, Orbicular Pharmaceutical Technologies, secured tentative U.S. FDA approval for a generic version of Ozempic (Semaglutide Injection). As the CDMO (Contract Development and Manufacturing Organization) partner, OneSource will manufacture this complex peptide at its Bangalore facility.
OneSource shares climbed to Rs. 1,624.40 on April 22, signaling that the “Ozempic” catalyst has outweighed the impact of Mukul Mahavir Agrawal’s stake reduction. Market sentiment remains bullish, with a 64.40% buy-side interest in the order book following the U.S. FDA tentative approval for generic Semaglutide.
The stock’s recovery from its January low of Rs. 1,057.00 suggests investors are prioritizing the company’s new role as a high-value CDMO over short-term portfolio rebalancing by marquee shareholders.
Company Overview
OneSource Specialty Pharma is a pure-play CDMO specializing in high-entry-barrier segments like biologics, sterile injectables, and complex peptides. With five US-FDA approved facilities and a 1,600-strong workforce, it serves as a key manufacturing partner for global pharma giants. Its flagship Bangalore plant is uniquely equipped for end-to-end production of “injector pen” drug-device combinations, critical for the Semaglutide (Ozempic) market.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor.
